ROCKVILLE, Md., Oct. 28 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that CPL Biologicals Pvt. Ltd., the new joint venture between Cadila Pharmaceuticals in India, has begun construction of a state-of-the-art manufacturing facility that will be used to produce pandemic and seasonal influenza vaccines. CPL Biologicals will utilize Novavax's virus-like particle (VLP) vaccine technology to produce commercial-scale quantities of VLP-based influenza vaccines using Novavax's innovative disposable manufacturing solution. The CPL Biologicals facility is expected to be operational within four months and should be capable of producing over 60 million doses annually at full capacity. This facility will also be used to produce other novel vaccines being developed by CPL Biologicals, based on Novavax's VLP vaccine technology.
"This new facility is being 100% supported financially by our partner, Cadila Pharmaceuticals Ltd. We anticipate creating sufficient capacity for CPL Biologicals to sell influenza vaccines in India and at the same time become a potential supplier to Novavax for sale of vaccines in other markets where Novavax maintains complete commercial rights," commented John Trizzino, Senior Vice President, International and Government Alliances for Novavax and Interim Chief Executive Officer of CPL Biologicals. "We believe this model will show how an efficient and scalable vaccine platform can help address the growing demand for pandemic and seasonal influenza vaccines. Moreover, the construction of this manufacturing facility is consistent with Novavax's strategy to establish regional partnerships and regional manufacturing capabilities that allow our VLP influenza vaccines to be licensed, manufactured and sold throughout the world."
Virus-like particles (VLPs) mimic the
|SOURCE Novavax, Inc.|
Copyright©2009 PR Newswire.
All rights reserved